ATTOR OCKET NO.: 08830-0342US1

T AND TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ACTING AS THE DESIGNATED/ELECTED OFFICE

In re: Patent application of: Gillian Lindy DURRANT

Appl. No.:

Not Yet Assigned

(International Application No. PCT/GB2003/005163)

Filed:

(International Filing Date: 26 November 2003 (26.11.2003))

For:

CD55-INTERACTION PARTNERS AND THE USES THEREOF

Mail Stop PCT Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

ATTN: DO/EO/US

INFORMATION DISCLOSURE STATEMENT

The present application is a 35 U.S.C. § 371 of PCT/GB2003/005163. Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith in duplicate as a substitute PTO Form 1449 listing the references cited in the Search Report in the international phase. A copy of the International Search Report is enclosed.

It is believed that copies of the references have been or will be forwarded by the International Search Authority. The Examiner is encouraged to contact the undersigned if reference copies have not been received.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10

EXPRESS MAIL Mailing Label Number:

EV320480848US

Date of Deposit:

May 27, 2005

I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to:

Mail Stop PCT, Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450.

Signature of person mailing page

KAREN M. SPINA

Type or print name of person

JC13 Rec'd PCT/PTO 27 MAY 2005

The Examiner is respectfully requested to review the items listed on the substitute PTO Form 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute PTO Form 1449, and return one copy to the undersigned.

This Information Disclosure Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist.

This Information Disclosure Statement is being submitted concurrently with the filing of the above-referenced application. Therefore, no certification, petition or fee is required. However, should a fee be due, authorization is hereby provided to charge Deposit Account No. 50-0573.

Respectfully submitted,

GILLIAN LINDY DURRANT

RY

DANIEL A. MONACO

Registration No. 30,480

DRINKER BIDDLE & REATH LLP

One Logan Square

18th and Cherry Streets

Philadelphia, PA 19103-6996

TEL.: (215) 988-3312

FAX: (215) 988-2757

Attorney for Applicant

JC13 Req CT/PTO 27 MAY 2009

Sheet 1 of 1 **SUBSTITUTE FORM PTO-1449** ATTY. DOCKET NO. U.S. DEPARTMENT OF COMMERCE APPLICATION NO. PATENT AND TRADEMARK OFFICE 08330-0342US1 Not Yet Known (I.A. PCT/GB2003/005163) INFORMATION DISCLOSURE STATEMENT APPLICANT: Gillian Lindy Durrant FILING DATE GROUP (I.A. 26 November 2003) Not Yet Known

U.S. PATENT DOCUMENTS

			TILDIVI DOGGNIZIVIO			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS .	SUBCLASS	FILING DATE (IF APPROPRIATE)
<u> </u>					<u> </u>	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	- 1
Α	WO 98/06838	19 Feb 1998	PCT	C12N	15/12		
В	WO 00/37489	29 June 2000	PCT	C07K	14/00		
		,					
		·					

OTHER DOCUMENTS (Including Author Title Date Pertinent Pages Ftc.)

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
C	Baldwin et al., "Monoclonal Antibody 791T/36 For Tumor Detection And Therapy For Metastases", Symposium On Fundamental Cancer Research 36:437-455 (1983)					
D	Spendlove et al., "Mapping The Binding Site Of A Novel Antibody To SCR-1 And 2 of CD55", <i>Immunology</i> 98(1): 101 (1999)					
Е	Bradley et al., "A Monoclonal Antibody Directed Against SCR1-2 Of Complement Control Protein, CD55 Enhances C3 Deposition And Tumor Cell Lysis", <i>British Journal Of Cancer</i> 88 (Supplement 1): S39 (2003)					
F	Pimm et al., "A Bispecific Monoclonal Antibody Against Methotrexate And A Human Tumor Associated Antigen Augments Cytotoxicity Of Methotrexate-Carrier Conjugate", British Journal Of Cancer 61(4): 508-513 (1990)					
G	Spendlove et al., "Decay Accelerating Factor (CD55): A Target For Cancer Vaccines?", Cancer Research 59(10): 2282-2286 (1999)					
Н	Hamann et al., "Characterization Of The CD55 (DAF)-Binding Site On The Seven-Span Transmembrane Receptor CD97", European Journal Of Immunology 28(5): 1701-1707 (1998)					

DATE CONSIDERED **EXAMINER**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.